All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
LevFinLevFin Leveraged Loans

Pharma fail: Concordia pulls bond as M&A flounders

Pills_230px

With pharma firms under intense scrutiny in the US, Concordia Healthcare Corp has dropped a planned $950m bond for its $3.5bn acquisition of Amdipharm Mercury, as the debt financing encountered some resistance from investors. Max Bower reports.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree